Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock Short Interest Report for October

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 109,110 shares, a drop of 35.4% from the September 30th total of 168,895 shares. Currently, 0.7% of the company’s shares are sold short. Based on an average trading volume of 97,400 shares, the days-to-cover ratio is presently 1.1 days.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on MRKR shares. Zacks Research upgraded Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a report on Friday, August 21st. Finally, Weiss Ratings raised Marker Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 19th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Marker Therapeutics Price Performance

NASDAQ:MRKR opened at $0.98 on Wednesday. Marker Therapeutics has a 1-year low of $0.84 and a 1-year high of $2.46. The firm has a 50 day simple moving average of $1.12 and a 200-day simple moving average of $1.36. The firm has a market cap of $16.38 million, a PE ratio of -2.40 and a beta of 1.65.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.16. As a group, sell-side analysts expect that Marker Therapeutics will post -0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Marker Therapeutics stock. Concurrent Investment Advisors LLC purchased a new position in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 67,963 shares of the company’s stock, valued at approximately $100,000. Concurrent Investment Advisors LLC owned 0.41% of Marker Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors.

The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.